Premium
Dendron‐Functionalized Polyglutamate‐Pyropheophorbide‐a Conjugates as Nanomedicines for Breast Cancer Photodynamic Therapy
Author(s) -
Wang Wenjia,
Zhang Qianfeng,
Li Zhiqian,
Zhang Jing,
Pan Dayi,
Wang Bing,
Zhu Hongyan,
Zhang Hu,
Gu Zhongwei,
Luo Kui
Publication year - 2021
Publication title -
macromolecular rapid communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.348
H-Index - 154
eISSN - 1521-3927
pISSN - 1022-1336
DOI - 10.1002/marc.202100013
Subject(s) - dendrimer , photodynamic therapy , conjugate , materials science , polyglutamic acid , cancer research , conjugated system , cancer cell , polymer , cancer , biophysics , chemistry , nanotechnology , polymer chemistry , medicine , biochemistry , organic chemistry , biology , mathematical analysis , mathematics , composite material
Photodynamic therapy (PDT) has shown its promise in the treatment of cancer. Herein, a dendron‐functionalized polyglutamic acid (PGA) polymer (PG‐L8G‐Ppa‐Dendron, PGPD) is synthesized and it is conjugated with pyropheophorbide‐a (Ppa) for the first time to treat triple negative breast cancer (TNBC), whereas a linear polyglutamate‐Ppa conjugate (PGP) is synthesized as a control. Compared to the linear counterpart, the glycosylated polymer‐based PGPD with a dendritic structure has excellent solubility and it self‐assembles to form uniform‐sized nanoparticles. PGPD displays a highly effective PDT effect in the animal model, evidenced with effective induction of reactive oxygen species (ROS) production and cell apoptosis. This may be due to an enhanced efficiency in delivery and accumulation of Ppa by this glycosylated dendritic polymer at tumor sites. Therefore, PGPD can be a highly effective and biosafe nanoagent for PDT of TNBC.